Articles

Get Ready for ISPOR 2026 International: Key Insights and Trends

ISPOR 2026 International is set to be a pivotal event for pharma professionals. Join us as we explore key insights and trends to watch.

US Cancer Clinics Rush for Revolution Medicines' New Pancreatic Cancer Drug

US cancer clinics are responding rapidly to the approval of Revolution Medicines' experimental drug for pancreatic cancer. This article explores the implications for stakeholders.

Political Contest in the U.K. Could Shake Up Drug Pricing

The ongoing political contest in the U.K. has significant implications for drug pricing. This article explores the potential impacts on the pharmaceutical industry.

Biotech Leaders Push for Pazdur Amid Takeda Layoffs

Biotech leaders are rallying for Pazdur's approval while Takeda announces significant layoffs. This article explores the implications for the pharma industry.

CDER Chief Høeg Fired: Implications for Pharma Industry

The firing of CDER Chief Høeg from the FDA raises questions about leadership stability and its effects on the pharmaceutical industry. This article explores the implications for pharma teams and investors.

India's Pharma Industry Goes Global: Can It Compete with China?

India's pharmaceutical sector is expanding internationally, but the question remains: can it rival China's dominance? This article explores the implications for the industry.

NICE Approval for Imfinzi: Implications for Stomach Cancer Treatment

NICE's backing of Imfinzi for stomach cancer marks a significant milestone for AstraZeneca. This article explores the implications for investors and pharma teams.

Amgen's 340B Program Crackdown: Implications for Pharma

Amgen has intensified its efforts against perceived misuse of the 340B program. This article explores the implications for pharmaceutical companies and stakeholders.

Holland & Knight Health Dose: Oncology Updates from May 12, 2026

This article provides a comprehensive analysis of the latest updates in oncology from the Holland & Knight Health Dose on May 12, 2026. Key insights for BD teams, investors, and analysts are highlighted.

Understanding the FDA: Insights on Marty Makary's Perspective

This article examines Marty Makary's views on the FDA, highlighting key misunderstandings and their implications for the pharmaceutical industry.

NICE Backs Imfinzi for Stomach Cancer: Implications for Investors

NICE's recent approval of Imfinzi for stomach cancer marks a significant milestone for AstraZeneca. This article explores the implications for investors and pharma teams.

Roche's ctDNA-Guided Approach in Bladder Cancer: A Strategic Win

Roche's innovative ctDNA-guided approach for Tecentriq in post-surgical bladder cancer has garnered significant attention. This article explores the implications for pharmaceutical teams and investors.

WHO Declares Ebola Outbreak an International Emergency

The WHO has declared the Ebola outbreak an international public health emergency, prompting critical responses from the pharmaceutical sector. This article explores the implications for business and investment.

The Cloudy Truth About Blue Zones: An Opinion Piece

This article delves into the realities of blue zones, challenging common perceptions and exploring their implications for the pharmaceutical sector.

ASCO 2026 Oncology Drug Pipeline Preview

Get an in-depth preview of the ASCO 2026 oncology drug pipeline, focusing on key presentations from leading pharma companies and their competitive positioning.

FDA Approves Eli Lilly's Zepbound for Obstructive Sleep Apnea

Eli Lilly's tirzepatide, branded as Zepbound, receives FDA approval for obstructive sleep apnea, marking a significant milestone in treatment options. This approval could reshape the competitive landscape and expand the GLP-1 class market.

BIO 2026 Preview: Companies to Watch and Key Catalysts

Get insights into the companies to watch and key catalysts for business development teams at the BIO International Convention 2026.

FDA Approval for Pfizer's Breast Cancer Drug: Vepdegestrant

The FDA has granted approval for Pfizer and Arvinas' novel breast cancer drug, vepdegestrant. This marks a significant new treatment option for patients with advanced or metastatic HR-positive, HER2-negative breast cancer who have exhausted prior endocrine therapies.

Auvelity FDA Approval: New MDD Treatment Option

The FDA has approved Auvelity, a new oral treatment for major depressive disorder (MDD) in adults, marking a significant advancement in mental health therapeutics. Manufactured by Axsome Therapeutics, this approval offers a novel option for patients seeking relief from MDD.

FDA Scrutiny Post-Market Data: Impact on Pharma Investment Strategies

This article examines the implications of FDA scrutiny on post-market data and its influence on pharmaceutical investment strategies and drug development.